Pharma and Imaging Companies interactions have progressed
The interim report for the second quarter and the first half of 2010 was approved by the Board of Directors on 18 August 2010. Please find the report and the investor presentation attached. Highlights from the report: ·Distributor sales continue to be slow and below expectations - BCtect® is promoted by the first clinic in UK and 6 more is starting after summer ·Strength of IP and competitive position drives Pharma and PET imaging companies’ interest in DiaGenic. Multiple interactions ongoing in Alzheimers area (ADtect/MCItect) ·New Board of Directors elected – more